To better understand the radioresistance of oral cancer cells and the role of the PI3K/AKT/mTOR signaling pathway in radiosensitization, inhibitors of the PI3K/AKT/mTOR pathway, such as BEZ235(Dactolisib), RAD001, and BKM120 (Buparlisib) [64], were used in radioresistant patient-derived OML-1R cells. The gene discussed is AKT1; the disease is lip and oral cavity carcinoma.